P1.03-28 Association Between Molecular Characteristics of CTNNB1 Mutations and Prognosis in Patients with Nsclc in Chinese Patients
J. Lai,C. Xu,W. Wang,Q. Zhang,W. Zhuang,Y. Huang,Y. Zhu,Y. Chen,G. Chen,M. Fang,T. Lv,Y. Song
DOI: https://doi.org/10.1016/j.jtho.2018.08.709
IF: 20.121
2018-01-01
Journal of Thoracic Oncology
Abstract:Recently, CTNNB1, encoding beta-catenin, is a well-known tumor-related gene in the wnt signaling pathway. While the genetic variability of CTNNB1 mutation NSCLC patients is unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring CTNNB1 mutations. A total of 677 patients with non-small-cell lung cancer were recruited between July 2012 and December 2015. The status of CTNNB1 mutation and other genes were detected by next generation sequencing. CTNNB1 gene mutation rate was 1.92% (13/677) in non-small cell lung cancer, including S33F (4 patients), S33C (1 patient), D32H (1 patient), G34R (1 patient), G34V (1 patient), G34del (1 patient), D11G (1 patient), S45P (1 patient), S45F (1 patient) and S45del plus S33Y (1 patient), and median overall survival (OS) for these patients was 12.0 months. Among them, all patients were CTNNB1 gene with co-occurring mutations. Briefly, patients with (n=7) or without (n=6) co-occurring EGFR mutations had a median OS of 25.8 months and 8.5 months respectively (P=0.18); patients with (n=10) or without (n=3) co-occurring TP53 mutations had a median OS of 10.0 months and 17.5 months respectively (P=0.35); patients with (n=2) or without (n=11) co-occurring BRAF mutations had a median OS of 7.5 months and 13.0 months respectively (P=0.14); patients with (n=2) or without (n=11) co-occurring ATM mutations had a median OS of 17.5 months and 11.0 months respectively (P=0.53). Accompanied gene has not well been connected with CTNNB1 gene mutations. Our finding expands the mutant spectrum of CTNNB1 gene and adds new understanding of the phenotype.